Syndax Pharmaceuticals Stock Market Value
| SNDX Stock | USD 19.71 0.18 0.90% |
| Symbol | Syndax |
Syndax Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Syndax Pharmaceuticals. If investors know Syndax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Syndax Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.40) | Revenue Per Share 0.045 | Quarterly Revenue Growth 332.974 | Return On Assets (0.40) | Return On Equity (0.63) |
The market value of Syndax Pharmaceuticals is measured differently than its book value, which is the value of Syndax that is recorded on the company's balance sheet. Investors also form their own opinion of Syndax Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Syndax Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Syndax Pharmaceuticals' market value can be influenced by many factors that don't directly affect Syndax Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Syndax Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Syndax Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Syndax Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Syndax Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Syndax Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Syndax Pharmaceuticals.
| 10/31/2022 |
| 10/20/2024 |
If you would invest 0.00 in Syndax Pharmaceuticals on October 31, 2022 and sell it all today you would earn a total of 0.00 from holding Syndax Pharmaceuticals or generate 0.0% return on investment in Syndax Pharmaceuticals over 720 days. Syndax Pharmaceuticals is related to or competes with Agilent Technologies, 23Andme Holding, DiaMedica Therapeutics, Valneva SE, Denali Therapeutics, Dianthus Therapeutics, and Vericel Corp. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer More
Syndax Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Syndax Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Syndax Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 15.02 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 4.02 |
Syndax Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Syndax Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Syndax Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Syndax Pharmaceuticals historical prices to predict the future Syndax Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.14) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Syndax Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Syndax Pharmaceuticals Backtested Returns
Syndax Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0829, which indicates the firm had a -0.0829% return per unit of risk over the last 3 months. Syndax Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Syndax Pharmaceuticals' Risk Adjusted Performance of (0.05), variance of 7.35, and Coefficient Of Variation of (1,283) to confirm the risk estimate we provide. The entity has a beta of 1.56, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Syndax Pharmaceuticals will likely underperform. At this point, Syndax Pharmaceuticals has a negative expected return of -0.23%. Please make sure to validate Syndax Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Syndax Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.17 |
Very weak predictability
Syndax Pharmaceuticals has very weak predictability. Overlapping area represents the amount of predictability between Syndax Pharmaceuticals time series from 31st of October 2022 to 26th of October 2023 and 26th of October 2023 to 20th of October 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Syndax Pharmaceuticals price movement. The serial correlation of 0.17 indicates that over 17.0% of current Syndax Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.17 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 6.7 |
Syndax Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Syndax Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Syndax Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Syndax Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Syndax Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Syndax Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Syndax Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Syndax Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Syndax Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Syndax Pharmaceuticals Lagged Returns
When evaluating Syndax Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Syndax Pharmaceuticals stock have on its future price. Syndax Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Syndax Pharmaceuticals autocorrelation shows the relationship between Syndax Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Syndax Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.